Literature DB >> 2311334

Clinical and pharmacokinetic properties of a transdermal nicotine patch.

S C Mulligan1, J G Masterson, J G Devane, J G Kelly.   

Abstract

We examined the pharmacokinetics of a transdermal nicotine patch and evaluated the usefulness of such a patch in a pilot smoking-cessation program. Use of the patch was associated with plasma nicotine concentrations that were comparable to smoking or to the use of other smoking-cessation devices. However, these plasma concentrations were maintained for 24 hours, and the patch appeared to be suitable for use once a day. Its use in a 6-week placebo-controlled double-blind study resulted in a significant degree of smoking cessation or in reduction of smoking activity. The findings suggest that it may be valuable to extend investigations to a larger population and that transdermal nicotine may have a useful role in smoking-cessation therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311334     DOI: 10.1038/clpt.1990.36

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Nasal nicotine spray: a rapid nicotine delivery system.

Authors:  G Sutherland; M A Russell; J Stapleton; C Feyerabend; O Ferno
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers.

Authors:  H D Ross; K K Chan; A J Piraino; V A John
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

3.  Sensitivity and tolerance to nicotine in smokers and nonsmokers.

Authors:  E D Srivastava; M A Russell; C Feyerabend; J G Masterson; J Rhodes
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Usage patterns of transdermal nicotine when purchased as a non-prescription medicine from pharmacies.

Authors:  J P Shaw; D G Ferry; D Pethica; D Brenner; I G Tucker
Journal:  Tob Control       Date:  1998       Impact factor: 7.552

5.  A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch.

Authors:  S Greenland; M H Satterfield; S F Lanes
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

6.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 7.  An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

Authors:  Kenneth A Perkins; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2013-12-03       Impact factor: 4.530

Review 8.  Chemical analyses as validators in smoking cessation programs.

Authors:  D D Gilbert
Journal:  J Behav Med       Date:  1993-06

9.  Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers.

Authors:  G M Kochak; J X Sun; R L Choi; A J Piraino
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

10.  Transdermal nicotine in smoking cessation. A meta-analysis.

Authors:  A Li Wan Po
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.